Results

Reset All Filters

Manufacturer:DCChemicals remove filter

Oncology

Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.

The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.

To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.

Click on the organs and learn more about cancer types

General information

Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.

Relevant products for oncology research

Name	Type	Specific against	Appl.	Item no.	Amount	Price
Naloxone (hydrochloride)	Chemicals	Other		DCC-DC26151-1g DCChemicals	1 g	Login Compare	Naloxone (hydrochloride)
Protease-activated receptor 2 (PAR2) agonist(SLIGKV-NH2)	Chemicals	Other		DCC-DC26219-1g DCChemicals	1 g	Login Compare	Protease-activated receptor 2 (PAR2) agonist(SLIGKV-NH2)
Cathepsin L inhibitor III	Inhibitors	Other		DCC-DC26058-1g DCChemicals	1 g	Login Compare	Cathepsin L inhibitor III
SIRT6 activator 12q	Chemicals	Other	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model	DCC-DC42568-100mg DCChemicals	100 mg	Login Compare	SIRT6 activator 12q
GSK046 (iBET-BD2)	Inhibitors	Other		DCC-DC39702-250mg DCChemicals	250 mg	Login Compare	GSK046 (iBET-BD2)
GSK046 (iBET-BD2)	Inhibitors	Other		DCC-DC39702-1g DCChemicals	1 g	Login Compare	GSK046 (iBET-BD2)
MSA-2	Chemicals	Other		DCC-DC39031-250mg DCChemicals	250 mg	Login Compare	MSA-2
MSA-2	Chemicals	Other		DCC-DC39031-1g DCChemicals	1 g	Login Compare	MSA-2
SIRT6 activator 12q	Chemicals	Other	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model	DCC-DC42568-250mg DCChemicals	250 mg	Login Compare	SIRT6 activator 12q
SIRT6 activator 12q	Chemicals	Other	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model	DCC-DC42568-1g DCChemicals	1 g	Login Compare	SIRT6 activator 12q
PD-1/PD-L1-IN 3	Inhibitors	Other		DCC-DC44154-100mg DCChemicals	100 mg	Login Compare	PD-1/PD-L1-IN 3
PD-1/PD-L1-IN 3	Inhibitors	Other		DCC-DC44154-25mg DCChemicals	25 mg	Login Compare	PD-1/PD-L1-IN 3
Complement factor D-IN-2	Chemicals	Other	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.	DCC-DC44151-250mg DCChemicals	250 mg	Login Compare	Complement factor D-IN-2
Arginase inhibitor 1	Inhibitors	Other		DCC-DC50092-100mg DCChemicals	100 mg	Login Compare	Arginase inhibitor 1
Arginase inhibitor 1	Inhibitors	Other		DCC-DC50092-250mg DCChemicals	250 mg	Login Compare	Arginase inhibitor 1
Arginase inhibitor 1	Inhibitors	Other		DCC-DC50092-1g DCChemicals	1 g	Login Compare	Arginase inhibitor 1
PD-1/PD-L1-IN 3	Inhibitors	Other		DCC-DC44154-10mg DCChemicals	10 mg	Login Compare	PD-1/PD-L1-IN 3
Complement factor D-IN-2	Chemicals	Other	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.	DCC-DC44151-100mg DCChemicals	100 mg	Login Compare	Complement factor D-IN-2
Complement factor D-IN-2	Chemicals	Other	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.	DCC-DC44151-1g DCChemicals	1 g	Login Compare	Complement factor D-IN-2
L19-TNF Biosimilar(Anti-Fibronectin Reference Antibody)		Other		DCC-A108-100mg DCChemicals	100 mg	Login Compare	L19-TNF Biosimilar(Anti-Fibronectin Reference Antibody)
Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)		Other		DCC-A107-100mg DCChemicals	100 mg	Login Compare	Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)
Raludotatug Biosimilar(Anti-CDH6 / K-Cadherin Reference Antibody)		Other		DCC-A1037-100mg DCChemicals	100 mg	Login Compare	Raludotatug Biosimilar(Anti-CDH6 / K-Cadherin Reference Antibody)
Codrituzumab-MMAE Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)		Other		DCC-A152-100mg DCChemicals	100 mg	Login Compare	Codrituzumab-MMAE Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)
Codrituzumab Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)		Other		DCC-A151-100mg DCChemicals	100 mg	Login Compare	Codrituzumab Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)
Amgen patent anti-beta amyloid Biosimilar(Anti-Amyloid Beta Reference Antibody )		Other		DCC-A672-100mg DCChemicals	100 mg	Login Compare	Amgen patent anti-beta amyloid Biosimilar(Anti-Amyloid Beta Reference Antibody )

Name Price

Naloxone (hydrochloride)

Type	Chemicals
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC26151-1g
Amount	1 g
Available

Protease-activated receptor 2 (PAR2) agonist(SLIGKV-NH2)

Type	Chemicals
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC26219-1g
Amount	1 g
Available

Cathepsin L inhibitor III

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC26058-1g
Amount	1 g
Available

SIRT6 activator 12q

Type	Chemicals
Clone
Specific against	Other
Appl.	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model
Host
Item no.	DCC-DC42568-100mg
Amount	100 mg
Available

GSK046 (iBET-BD2)

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC39702-250mg
Amount	250 mg
Available

GSK046 (iBET-BD2)

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC39702-1g
Amount	1 g
Available

MSA-2

Type	Chemicals
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC39031-250mg
Amount	250 mg
Available

MSA-2

Type	Chemicals
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC39031-1g
Amount	1 g
Available

SIRT6 activator 12q

Type	Chemicals
Clone
Specific against	Other
Appl.	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model
Host
Item no.	DCC-DC42568-250mg
Amount	250 mg
Available

SIRT6 activator 12q

Type	Chemicals
Clone
Specific against	Other
Appl.	Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model
Host
Item no.	DCC-DC42568-1g
Amount	1 g
Available

PD-1/PD-L1-IN 3

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC44154-100mg
Amount	100 mg
Available

PD-1/PD-L1-IN 3

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC44154-25mg
Amount	25 mg
Available

Complement factor D-IN-2

Type	Chemicals
Clone
Specific against	Other
Appl.	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
Host
Item no.	DCC-DC44151-250mg
Amount	250 mg
Available

Arginase inhibitor 1

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC50092-100mg
Amount	100 mg
Available

Arginase inhibitor 1

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC50092-250mg
Amount	250 mg
Available

Arginase inhibitor 1

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC50092-1g
Amount	1 g
Available

PD-1/PD-L1-IN 3

Type	Inhibitors
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-DC44154-10mg
Amount	10 mg
Available

Complement factor D-IN-2

Type	Chemicals
Clone
Specific against	Other
Appl.	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
Host
Item no.	DCC-DC44151-100mg
Amount	100 mg
Available

Complement factor D-IN-2

Type	Chemicals
Clone
Specific against	Other
Appl.	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
Host
Item no.	DCC-DC44151-1g
Amount	1 g
Available

L19-TNF Biosimilar(Anti-Fibronectin Reference Antibody)

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A108-100mg
Amount	100 mg
Available

Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A107-100mg
Amount	100 mg
Available

Raludotatug Biosimilar(Anti-CDH6 / K-Cadherin Reference Antibody)

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A1037-100mg
Amount	100 mg
Available

Codrituzumab-MMAE Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A152-100mg
Amount	100 mg
Available

Codrituzumab Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A151-100mg
Amount	100 mg
Available

Amgen patent anti-beta amyloid Biosimilar(Anti-Amyloid Beta Reference Antibody )

Type
Clone
Specific against	Other
Appl.
Host
Item no.	DCC-A672-100mg
Amount	100 mg
Available

Oncology

Click on the organs and learn more about cancer types

General information

Relevant products for oncology research

Contact

About Hölzel

Service

Infodesk

REGISTER & SECURE BENEFITS

Filter Results

Oncology

Click on the organs and learn more about cancer types

General information

Relevant products for oncology research

Contact

About Hölzel

Service

Infodesk